BLRX BioLineRx Ltd.

1.14
0  -5%
Previous Close 1.20
Open 1.25
Price To book 1.75
Market Cap 64.33M
Shares 56,432,000
Volume 1,387,990
Short Ratio 0.30
Av. Daily Volume 397,528

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial initiation announced January 17, 2017.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Development plans to be released by early 2017.
BL-7010
Gluten sensitivity
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BL-8040
Consolidation treatment for AML cancer patients
Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017.
BL-8040
Mobilization and collection of bone marrow stem cells
Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040
Acute myeloid leukemia (AML) cancer relapsed and refractory

Latest News

  1. 7:01 am BioLineRx reports partial results data from its open-label Phase 2 trial for BL-8040 as a novel monotherapy approach for the mobilization and collection of blood forming stem and progenitor cells from the peripheral blood; top-line
  2. BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
  3. BioLineRx to Report Annual 2016 Results on March 23, 2017
  4. Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc. (AMAG)
  5. Coverage initiated on BioLineRx by Rodman & Renshaw
  6. BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
  7. BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
  8. BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
  9. BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco
  10. BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
  11. BioLineRx Reports Third Quarter 2016 Financial Results
  12. BioLineRx Reports Third Quarter 2016 Financial Results
  13. BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
  14. BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
  15. BioLineRx to Report Third Quarter Results on November 22, 2016
  16. BioLineRx to Report Third Quarter Results on November 22, 2016
  17. Penny Ante: Ante Up For Bioline RX Ltd (BLRX) Stock
  18. BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
  19. BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
  20. BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting